Indeed, the in vivo antitumor potential of Conatumumab, a fully human agonistic targeting DR5, was demonstrated to require FcR-mediated crosslinking to inhibit tumor growth [158,159]. The gene discussed is TNFRSF10B; the disease is neoplasm.